Brainstorm Cell Therapeutics IncNASDAQ:BCLINASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.3700
- TODAY'S CHANGE (%)-0.0165 (-4.2691%)
- Bid / Lots0.3700/ 96
- Ask / Lots0.3949/ 4
- Open / Previous Close0.3970 / 0.3865
- Day Range
- 52 Week Range
- Volume564,214
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BCLI |
|---|---|---|
| 09:32 ET | 1132 | 0.4 |
| 09:34 ET | 8639 | 0.39 |
| 09:36 ET | 600 | 0.39 |
| 09:39 ET | 3000 | 0.3905 |
| 09:41 ET | 100 | 0.3905 |
| 09:54 ET | 931 | 0.39792 |
| 09:56 ET | 1300 | 0.3904 |
| 10:01 ET | 6213 | 0.3905 |
| 10:03 ET | 100 | 0.3905 |
| 10:06 ET | 600 | 0.39 |
| 10:08 ET | 397 | 0.399 |
| 10:10 ET | 2200 | 0.391 |
| 10:12 ET | 600 | 0.392 |
| 10:15 ET | 200 | 0.3998 |
| 10:17 ET | 850 | 0.3961 |
| 10:19 ET | 1100 | 0.396 |
| 10:21 ET | 2300 | 0.398 |
| 10:24 ET | 1700 | 0.396 |
| 10:26 ET | 1500 | 0.397 |
| 10:28 ET | 300 | 0.397 |
| 10:30 ET | 614 | 0.396785 |
| 10:32 ET | 3100 | 0.392 |
| 10:33 ET | 200 | 0.3916 |
| 10:35 ET | 628 | 0.39289 |
| 10:37 ET | 200 | 0.3915 |
| 10:44 ET | 200 | 0.3915 |
| 10:51 ET | 400 | 0.39 |
| 10:53 ET | 100 | 0.3909 |
| 10:57 ET | 1150 | 0.3918 |
| 11:00 ET | 1941 | 0.3835 |
| 11:02 ET | 3124 | 0.3918 |
| 11:04 ET | 4701 | 0.388 |
| 11:09 ET | 122 | 0.3835 |
| 11:11 ET | 205 | 0.387 |
| 11:13 ET | 1002 | 0.387 |
| 11:15 ET | 100 | 0.3875 |
| 11:18 ET | 1941 | 0.3879 |
| 11:20 ET | 2470 | 0.39 |
| 11:22 ET | 2394 | 0.39 |
| 11:26 ET | 100 | 0.39 |
| 11:27 ET | 388 | 0.3895 |
| 11:29 ET | 2100 | 0.389 |
| 11:33 ET | 701 | 0.389 |
| 11:38 ET | 1266 | 0.3835 |
| 11:58 ET | 257 | 0.3836 |
| 12:12 ET | 300 | 0.3876 |
| 12:14 ET | 518 | 0.3842 |
| 12:18 ET | 8908 | 0.3842 |
| 12:20 ET | 13019 | 0.3861 |
| 12:23 ET | 5300 | 0.3861 |
| 12:25 ET | 1400 | 0.3861 |
| 12:34 ET | 125 | 0.387 |
| 12:36 ET | 400 | 0.3861 |
| 12:41 ET | 100 | 0.3869 |
| 12:43 ET | 500 | 0.3869 |
| 12:52 ET | 1218 | 0.3842 |
| 12:57 ET | 1200 | 0.3859 |
| 12:59 ET | 100 | 0.3859 |
| 01:03 ET | 400 | 0.3859 |
| 01:06 ET | 200 | 0.3859 |
| 01:14 ET | 200 | 0.3859 |
| 01:17 ET | 400 | 0.3866 |
| 01:19 ET | 200 | 0.3859 |
| 01:21 ET | 100 | 0.3859 |
| 01:26 ET | 421 | 0.3844 |
| 01:28 ET | 200 | 0.385 |
| 01:37 ET | 100 | 0.385 |
| 01:39 ET | 200 | 0.386 |
| 01:42 ET | 1000 | 0.385 |
| 01:46 ET | 1907 | 0.3855 |
| 02:00 ET | 700 | 0.385899 |
| 02:02 ET | 100 | 0.3852 |
| 02:09 ET | 315 | 0.3852 |
| 02:11 ET | 200 | 0.3844 |
| 02:13 ET | 103 | 0.3843 |
| 02:15 ET | 6100 | 0.3851 |
| 02:18 ET | 259 | 0.3842 |
| 02:20 ET | 100 | 0.3851 |
| 02:26 ET | 100 | 0.3851 |
| 02:27 ET | 300 | 0.3852 |
| 02:33 ET | 9088 | 0.386 |
| 02:40 ET | 319 | 0.385 |
| 02:42 ET | 46364 | 0.3855 |
| 02:44 ET | 1797 | 0.391299 |
| 02:45 ET | 900 | 0.3912 |
| 02:56 ET | 1500 | 0.3891 |
| 02:58 ET | 6147 | 0.3843 |
| 03:03 ET | 520 | 0.39 |
| 03:05 ET | 300 | 0.386 |
| 03:07 ET | 3474 | 0.3891 |
| 03:14 ET | 2451 | 0.386 |
| 03:20 ET | 207 | 0.3905 |
| 03:21 ET | 300 | 0.38925 |
| 03:23 ET | 15746 | 0.3923 |
| 03:25 ET | 1630 | 0.3884 |
| 03:30 ET | 521 | 0.385 |
| 03:32 ET | 2574 | 0.3875 |
| 03:36 ET | 100 | 0.3843 |
| 03:38 ET | 500 | 0.3893 |
| 03:39 ET | 200 | 0.3893 |
| 03:43 ET | 100 | 0.3842 |
| 03:52 ET | 4686 | 0.3835 |
| 03:54 ET | 1000 | 0.3835 |
| 03:56 ET | 600 | 0.3835 |
| 03:57 ET | 660 | 0.3857 |
| 03:59 ET | 198560 | 0.37 |
Jun 20, 2024
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer, from 6:00AM ET on Thursday Jun 20, 2024 by Dow Jones
6:00AM ET on Thursday Jun 20, 2024 by Dow Jones*DJ BrainStorm Cell Therapeutics Announces Appointment Of Haro Hartounian Ph.D. As Chief Operating Officer >GHDN.BE, from 6:00AM ET on Thursday Jun 20, 2024 by Dow Jones
6:00AM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 14, 2024
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn Clinical Effectiveness Expectation, from 12:01PM ET on Friday Jun 14, 2024 by Dow Jones
12:01PM ET on Friday Jun 14, 2024 by Dow JonesBCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn(R) Clinical Effectiveness Expectation, from 12:01PM ET on Friday Jun 14, 2024 by Dow Jones
12:01PM ET on Friday Jun 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Brainstorm Cell Therapeutics Inc | 25.9M | -1.1x | --- |
RenovoRx Inc | 26.3M | -1.5x | --- |
Janone Inc | 26.5M | -0.6x | --- |
Cocrystal Pharma Inc | 27.1M | -1.6x | --- |
Viracta Therapeutics Inc | 24.6M | -0.5x | --- |
Alterola Biotech Inc | 27.3M | -7.5x | --- |
Company Information
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
Contact Information
- Headquarters
- 1325 Avenue Of Americas, 28Th FloorNEW YORK, NY, United States 10019
- Phone
- 201-488-0460
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Jacob Frenkel
- President, Chief Executive Officer
- Chaim Lebovits
- Independent Vice Chairman of the Board
- Irit Arbel
- Chief Financial Officer, Controller
- Alla Patlis
- Executive Vice President, Chief Business Officer, Secretary, Director
- Uri Yablonka
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $25.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.37 |
EPS | $-0.32 |
Book Value | $-0.08 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
